A Q&A With Lilly Biomedicines President Christi Shaw
The Eli Lilly & Co. executive talked with Scrip about the competitive dynamics facing Taltz, the status of baricitinib and launching galcanezumab in the crowded CGRP class, as well as about industry issues like drug rebates, drug pricing and gender diversity.
You may also be interested in...
After heading up Lilly Bio-Medicines for two-and-a-half years, Shaw will take over Gilead’s gene therapy subsidiary. At Lilly, she oversaw the approvals of Olumiant and Emgality and helped grow Taltz.
AbbVie could be looking at near-simultaneous launches for Skyrizi on both sides of the Atlantic after the psoriasis drug – a key future growth driver – got a positive opinion from Europe's regulators some two months before the FDA is due to give its verdict on the interleukin-23 inhibitor.
Key strategy updates are coming: GSK will unveil its new R&D approach, Biogen will update investors on its Alzheimer's plans, and investors are keen to find out whether or not Lilly will sell its animal health franchise. Investors will also be keeping an eye on how Gilead is faring with its move into oncology.